Success Metrics

Clinical Success Rate
75.0%

Based on 45 completed trials

Completion Rate
75%(45/60)
Active Trials
9(9%)
Results Posted
38%(17 trials)
Terminated
15(16%)

Phase Distribution

Ph phase_3
27
28%
Ph phase_2
38
40%
Ph phase_4
10
10%
Ph not_applicable
3
3%
Ph early_phase_1
1
1%
Ph phase_1
15
16%

Phase Distribution

16

Early Stage

38

Mid Stage

37

Late Stage

Phase Distribution94 total trials
Early Phase 1First-in-human
1(1.1%)
Phase 1Safety & dosage
15(16.0%)
Phase 2Efficacy & side effects
38(40.4%)
Phase 3Large-scale testing
27(28.7%)
Phase 4Post-market surveillance
10(10.6%)
N/ANon-phased studies
3(3.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.6%

45 of 62 finished

Non-Completion Rate

27.4%

17 ended early

Currently Active

9

trials recruiting

Total Trials

96

all time

Status Distribution
Active(14)
Completed(45)
Terminated(17)
Other(20)

Detailed Status

Completed45
unknown20
Terminated15
Not yet recruiting5
Active, not recruiting5
Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
96
Active
9
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.1%)
Phase 115 (16.0%)
Phase 238 (40.4%)
Phase 327 (28.7%)
Phase 410 (10.6%)
N/A3 (3.2%)

Trials by Status

not_yet_recruiting55%
active_not_recruiting55%
recruiting44%
completed4547%
unknown2021%
withdrawn22%
terminated1516%

Recent Activity

9 active trials
Showing 5 of 96
not_yet_recruitingphase_3

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )

NCT07566156
recruitingphase_1

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

NCT04847063
active_not_recruitingphase_3

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764
not_yet_recruitingphase_4

Hyaluronic Acid vs Mitomycin-C in External Dacryocystorhinostomy

NCT07504250
not_yet_recruitingphase_2

Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

NCT07475286
View all 96 trials

Clinical Trials (96)

Showing 20 of 96 trialsScroll for more
NCT07566156Phase 3

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )

Not Yet Recruiting
NCT04847063Phase 1

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

Recruiting
NCT06211764Phase 3

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

Active Not Recruiting
NCT07504250Phase 4

Hyaluronic Acid vs Mitomycin-C in External Dacryocystorhinostomy

Not Yet Recruiting
NCT07475286Phase 2

Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

Not Yet Recruiting
NCT06919965Phase 3

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Recruiting
NCT03348969Phase 4

Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC

Completed
NCT06513065Phase 3

Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)

Recruiting
NCT05902533Phase 2

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

Active Not Recruiting
NCT06781879Phase 4

Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer

Recruiting
NCT02106572Phase 3

Therapeutic Instillation of Mistletoe

Active Not Recruiting
NCT04200417Phase 1

Chemoembolization for Lung Tumors

Completed
NCT03092518Phase 2

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

Completed
NCT02299999Phase 2

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active Not Recruiting
NCT01167725Phase 3

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Terminated
NCT02710734Phase 2

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Active Not Recruiting
NCT06680245Phase 3

Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery

Not Yet Recruiting
NCT03658304Phase 2

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

Completed
NCT02040142Phase 2

HIPEC for Peritoneal Carcinomatosis

Completed
NCT06232005Phase 2

Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture

Completed

Drug Details

Intervention Type
DRUG
Total Trials
96